Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
That said, only 14% of drugs in clinical trials make it to FDA approval, according to Research from MIT ... This update came ...
GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase IIIData presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback